Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial - Wikidata - wikimedia - TriplyDB

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

http://www.wikidata.org/entity/Q28294857

about

Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science What is the Need for Prostatic Biomarkers in Prostate Cancer Management?Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Chemotherapy and its evolving role in the management of advanced prostate cancer The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer Chemotherapy options in castration-resistant prostate cancer 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.The best of both worlds - managing the cancer, saving the bone.The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis.shRNA-mediated GSTP1 gene silencing enhances androgen-independent cell line DU145 chemosensitivity.Docetaxel-based therapy with and without antiangiogenic agents as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of nine randomized controlled trials.Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800).Drugs that offer a survival advantage for men with bone metastases resulting from castration-resistant prostate cancer: new and emerging treatment options.Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.Circulating tumor cells in prostate cancer.Therapeutic options and multifaceted treatment paradigms in metastatic castrate-resistant prostate cancer.Managing bone metastases and reducing skeletal related events in prostate cancer.Cytotoxic chemotherapy in the contemporary management of metastatic castration-resistant prostate cancer (mCRPC).PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials.Contemporary pharmacotherapy for the prevention of skeletal complications in patients with prostate cancer.Targeting neuroendocrine prostate cancer: molecular and clinical perspectives.The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.Sequences and combinations of multifaceted therapy in advanced prostate cancer.Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer.Chemotherapy in Prostate Cancer.Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.Targeted Agents in Preclinical and Early Clinical Development for the Treatment of Cancer Bone Metastases.Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.Cardiovascular toxicities of systemic treatments of prostate cancer.Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials.Genomic tests to guide prostate cancer management following diagnosis.Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis.

P2860

Q26772883-09533162-51A6-4ABF-8306-B7A0DEE9B147 Q26798425-A8802112-4A0F-4EDE-89EF-5876B67A6EF5 Q26852544-2520E406-E331-43F9-88BF-07F097AC51B0 Q27008883-FC09B79D-69B7-4A3C-A020-4A43801CC52D Q27009064-88DB856B-A64E-49C5-A092-DEAC2F3BD850 Q27011642-7EC5B10D-F144-449F-8B91-F720D789ACCB Q27334654-D96922F4-15E5-4048-9FEA-D7E561B67DF5 Q28075965-885302EB-D12E-4EF9-8D57-99647C25CF3C Q28078477-C6517088-C18E-476A-85A5-89E227725AD2 Q30239808-AD153F25-38ED-47A7-9DAB-7B0E4809C2D3 Q30574916-87E06255-FC27-4303-838C-37C7355EF445 Q33441119-A33067D6-A65E-4F45-A8B4-28D7B0C97BA1 Q33920055-8EEB134A-987D-432C-8821-2FDF41A42983 Q34699785-52428EB1-F4E7-4C4E-9BC7-53B5409EAE17 Q35064696-8651D75B-C3A4-4927-8762-A6D64CB25839 Q35298058-3950D861-7772-47B2-8671-7743CC8D84F3 Q35328550-C1B32DB1-D26F-4AD0-A05C-7F7A4F4993E6 Q35698539-84112DD1-A5B5-4DC2-A7AB-C7A4D900DA73 Q35948297-2222D003-6063-4A58-A56F-C59293E87794 Q36260345-6DACAB64-0F2E-4D1C-AC5A-49326E8E1405 Q37641292-211AFA94-0DCC-4FE5-B391-CD6ADCA02371 Q37696687-6B55C95C-CEE6-4E94-BB91-3924037CD07A Q38168685-8E55CA95-178D-4F8D-A808-397516789317 Q38195723-5D7030D5-A0B5-4438-8846-C2BC7FC66B41 Q38211359-B9F6B415-CEFC-408F-8218-B8F25B20099A Q38232184-4EAC0AAD-9372-466C-853B-A69D82F4949F Q38246587-0CF0C62D-FB0A-4D52-8B94-CB5F98CFAD41 Q38252425-B49A18D3-62D7-492C-9517-F5D6CF8BC283 Q38362686-741656E5-6C7B-46F4-BDFA-CEC89D6E8115 Q38374417-7FDA84C5-C55D-4C94-A49B-402BC6E890DE Q38391800-90C482D3-639B-450E-9B40-A05143B3B4EF Q38438248-007A08CC-3252-41E7-B4A0-8F5168AA6274 Q38555599-30874DFD-E47E-4C5E-9C20-CCB4E31F0F3D Q38600919-A8DD8A47-C8DE-47F9-A5F8-888E5F4342B8 Q38700342-B91A67DC-0927-468F-8F78-46B22ECA9C32 Q38745926-42BC5B8A-9761-4C5A-A711-65CCB1744979 Q39002111-7ADAB4C1-3B82-44A9-91A0-EBB8CA819A35 Q39106330-831663D3-5F8E-4B89-97E1-CC821F362C4B Q39170943-1AC7868C-15F7-4F1D-91FF-3D315C833A52 Q40846608-04F0C4B5-FFA6-4C2B-951B-56426D2A2008

P2860

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

http://www.wikidata.org/entity/Q28294857

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Docetaxel and atrasentan versu ...... 1): a randomised phase 3 trial

@ast

Docetaxel and atrasentan versu ...... 1): a randomised phase 3 trial

@en

Docetaxel and atrasentan versu ...... 1): a randomised phase 3 trial

@nl

type

label

Docetaxel and atrasentan versu ...... 1): a randomised phase 3 trial

@ast

Docetaxel and atrasentan versu ...... 1): a randomised phase 3 trial

@en

Docetaxel and atrasentan versu ...... 1): a randomised phase 3 trial

@nl

prefLabel

Docetaxel and atrasentan versu ...... 1): a randomised phase 3 trial

@ast

Docetaxel and atrasentan versu ...... 1): a randomised phase 3 trial

@en

Docetaxel and atrasentan versu ...... 1): a randomised phase 3 trial

@nl

P1433

Q28294857-A2DD59ED-25F8-474F-AC59-B71A5F2182E3

P1476

Q28294857-7DF1EC7C-7941-46FB-88CD-413D56C15BF8

P2093

Q28294857-02AFD09B-A6D9-4B75-ADFF-52AA8B42F7B7

Q28294857-0E9CF7D8-10BC-45A9-A7D8-85FA307237F3

Q28294857-2D3264C3-1455-4430-9069-DC065EAE5806

Q28294857-3E86A7CB-5E0C-4809-AFF4-6A37939B0AD3

Q28294857-6D19C3C8-6810-45D7-AB04-2F8F862E8629

Q28294857-76DBDDFA-CE1D-4CCA-8A1D-79463544FE65

Q28294857-792E8B1A-50D4-42B6-A88F-8F8C478FF1CC

Q28294857-80A800FE-6A17-4371-9070-12CC2B3B27B8

Q28294857-A65E2245-FBA1-43AD-A950-AF72781FA7F7

Q28294857-A88C5BA2-2A8B-4C4A-93B4-AA8D249E4AB5

P2860

Q28294857-191880DE-866D-4A18-BCC1-D4AF065D8E6F

Q28294857-20FA58F7-0E9A-4807-8A75-F33FA753FFC2

Q28294857-2405D254-181D-4E10-B1C8-EC2098087A87

Q28294857-26B949D3-F17B-4BA8-9DC2-AA360C8ACFF9

Q28294857-359EBB4B-9E88-42F6-B09A-9F27521ECB2F

Q28294857-3A04AE69-4983-4123-894D-A92636203C99

Q28294857-3C9D08CA-6CF9-439D-9B04-55FF3AC5B15E

Q28294857-46F1C00F-7790-4437-9029-C4A50B5067BF

Q28294857-4D25FF94-A85F-44AE-BC0B-E263D0AFE565

Q28294857-5315256A-5CF1-4F66-A69B-3E63D052C451

P304

Q28294857-FE981154-98FE-4BA0-8D7B-BEC764602C8D

P31

Q28294857-033A919F-D16C-4BD5-A346-3DAF28BD14ED

P3181

Q28294857-C679E010-6F32-4B15-B9D9-9B4089C049DA

P356

Q28294857-C83D125D-4473-49FC-8401-FC698677E7DF

P407

Q28294857-A78A2F69-7563-42E5-A7D0-74F11A37E9F3

P433

Q28294857-546073EF-2D7E-4936-927A-11BA75E16C9A

P478

Q28294857-969F8404-E3EC-42E2-85C2-A86FA8A578EC

P50

Q28294857-1D70F233-5102-498F-97A1-3A73FA48A540

P577

Q28294857-ECEFFB40-C86A-4A2F-A72E-34A681ECD796

P5875

Q28294857-AF373712-6F57-47ED-BDDC-A826ACF99F11

P698

Q28294857-133EAFE4-5A68-443C-BC02-82C4ABD0D3D0

P921

Q28294857-0772DD9B-5684-4739-AB21-7D57F4576A02

Q28294857-5593FA7F-3A7F-4539-AF0D-568D2222F68D

P932

Q28294857-0220EFED-975F-43E3-88A7-1043016F1CDE

P3181

P356

S1470-2045(13)70294-8

P1433

The Lancet Oncology

P1476

Docetaxel and atrasentan versu ...... 1): a randomised phase 3 trial

@en

P2093

Amir Goldkorn

http://www.w3.org/2001/XMLSchema#string

Carol M Moinpour

http://www.w3.org/2001/XMLSchema#string

Catherine M Tangen

http://www.w3.org/2001/XMLSchema#string

Celestia S Higano

http://www.w3.org/2001/XMLSchema#string

Ian M Thompson

http://www.w3.org/2001/XMLSchema#string

J Paul Monk

http://www.w3.org/2001/XMLSchema#string

Maha Hussain

http://www.w3.org/2001/XMLSchema#string

Mark G Garzotto

http://www.w3.org/2001/XMLSchema#string

Michael A Carducci

http://www.w3.org/2001/XMLSchema#string

Neeraj Agarwal

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.

Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.

Endothelin-1 and osteoblastic metastasis

P304

893-900

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3074571

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S1470-2045(13)70294-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

250922923

http://www.w3.org/2001/XMLSchema#string

P698

23871417

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial

P932

4277263

http://www.w3.org/2001/XMLSchema#string